Your search for smoking cessation returned 33 results

Benefits of smoking cessation medications decline over the first year.

The researchers analyzed the medical records of 56,851 new users of varenicline.

The data showed TNP was significantly more effective vs. no medication assisted quit attempts for males (odds ratio [OR] 1.37, 95% CI: 1.02, 1.83; P=0.03) but not for females (OR 0.96, 95% CI: 0.71, 1.31; P=0.82).

The FDA determined the benefits of this smoking cessation therapy outweighed the potential risks.

According to a study in The American Journal of Drug and Alcohol Abuse, psilocybin showed promise in promoting long-term smoking abstinence in the context of a structured treatment program.

Varenicline did not increase the rate of cardiovascular (CV) serious adverse events, according to data from a systematic review published in the Journal of the American Heart Association.

Researchers found no significant differences in rates of smoking abstinence at 26 or 52 weeks following a 12-week treatment with a nicotine patch, varenicline, or combination nicotine replacement therapy (nicotine patch + nicotine lozenge [C-NRT]), in adults trying to quit smoking.

A bacterial enzyme may be a future candidate in smoking cessation, according to a new study led by researchers at The Scripps Institute.

The National Comprehensive Cancer Network (NCCN) has released Clinical Practice Guidelines in Oncology for Smoking Cessation.

According to a study in Nicotine & Tobacco Research, the relative coronary heart disease (CHD) risk is greater for smokers who consume cigarettes over a longer period of time vs. smokers who consume the same quantity over a shorter period.